Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Flexion Therapeutics, Inc. (NASDAQ:FLXN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 100,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,022,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS owned about 0.31% of Flexion Therapeutics at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Teachers Advisors LLC raised its position in shares of Flexion Therapeutics by 21.2% in the fourth quarter. Teachers Advisors LLC now owns 43,468 shares of the specialty pharmaceutical company’s stock valued at $827,000 after buying an additional 7,610 shares during the last quarter. Bank of Montreal Can boosted its stake in Flexion Therapeutics by 15.1% during the first quarter. Bank of Montreal Can now owns 82,020 shares of the specialty pharmaceutical company’s stock worth $2,207,000 after buying an additional 10,750 shares during the period. Janney Montgomery Scott LLC boosted its stake in Flexion Therapeutics by 30.8% during the first quarter. Janney Montgomery Scott LLC now owns 13,575 shares of the specialty pharmaceutical company’s stock worth $365,000 after buying an additional 3,200 shares during the period. Wells Fargo & Company MN boosted its stake in Flexion Therapeutics by 25.1% during the first quarter. Wells Fargo & Company MN now owns 124,717 shares of the specialty pharmaceutical company’s stock worth $3,356,000 after buying an additional 25,047 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new position in Flexion Therapeutics during the first quarter worth about $2,018,000. 82.75% of the stock is currently owned by institutional investors and hedge funds.

In other Flexion Therapeutics news, Director Mark Stejbach acquired 1,580 shares of the business’s stock in a transaction on Friday, June 16th. The stock was purchased at an average price of $17.02 per share, for a total transaction of $26,891.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 15.98% of the stock is owned by company insiders.

FLXN has been the subject of several recent research reports. BMO Capital Markets reissued a “buy” rating on shares of Flexion Therapeutics in a research note on Friday, August 11th. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price objective (up previously from $34.00) on shares of Flexion Therapeutics in a research note on Thursday, August 10th. Cantor Fitzgerald set a $40.00 price objective on shares of Flexion Therapeutics and gave the company a “buy” rating in a research note on Monday, June 12th. Janney Montgomery Scott reissued a “buy” rating and issued a $35.00 price objective (up previously from $30.00) on shares of Flexion Therapeutics in a research note on Wednesday, July 12th. Finally, Royal Bank Of Canada reissued a “buy” rating and issued a $44.00 price objective on shares of Flexion Therapeutics in a research note on Friday, July 7th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $31.50.

Shares of Flexion Therapeutics, Inc. (NASDAQ FLXN) opened at 23.87 on Friday. The stock’s market cap is $761.57 million. The stock’s 50 day moving average price is $23.30 and its 200-day moving average price is $21.85. Flexion Therapeutics, Inc. has a one year low of $15.44 and a one year high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by $0.11. On average, equities analysts predict that Flexion Therapeutics, Inc. will post ($3.70) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Commonwealth of Pennsylvania Public School Empls Retrmt SYS Takes $2.02 Million Position in Flexion Therapeutics, Inc. (FLXN)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/08/commonwealth-of-pennsylvania-public-school-empls-retrmt-sys-takes-2-02-million-position-in-flexion-therapeutics-inc-flxn.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.